可切除非小细胞肺癌的新辅助治疗和辅助治疗 (NeoCOAST-2)
可切除的早期(II 至 IIIB)非小细胞肺癌患者新辅助治疗和辅助治疗的 II 期、开放标签、多中心、随机研究 (NeoCOAST-2)
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
研究概览
地位
条件
详细说明
This is an open-label, multi-arms, multicentre, randomised study, eligible participants will be enrolled and randomised to one of the following treatment regimens.
Arm 1: Participants will receive Oleclumab + durvalumab + CTX as neoadjuvant treatment and Oleclumab + durvalumab as adjuvant treatment.
Arm 2: Participants will receive Monalizumab + durvalumab + CTX as neoadjuvant treatment and Monalizumab + durvalumab as adjuvant treatment.
Arm 3: Participants will receive Volrustomig (Dose Exploration) + CTX as neoadjuvant treatment and Volrustomig as adjuvant treatment.
Arm 4: Participants will receive Dato-DXd + durvalumab + single agent platinum chemotherapy as neoadjuvant treatment and durvalumab as adjuvant treatment.
Arm 5: Participants will receive AZD0171 + durvalumab + CTX as neoadjuvant treatment and AZD0171 + durvalumab as adjuvant treatment.
Arm 6: Participants will receive Rilvegostomig + CTX as neoadjuvant treatment and Rilvegostomig as adjuvant treatment.
Arm 7: Participants will receive Dato-DXd + Rilvegostomig + single agent platinum chemotherapy as neoadjuvant treatment and Rilvegostomig as adjuvant treatment.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:AstraZeneca Clinical Study Information Center
- 电话号码:1-877-240-9479
- 邮箱:information.center@astrazeneca.com
研究联系人备份
- 姓名:AstraZeneca Lung Cancer Study Locator Service
- 电话号码:1-884-432-3892
- 邮箱:az-lcsl@careboxhealth.com
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1Z2
- 完全的
- Research Site
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R3E 0V9
- 招聘中
- Research Site
-
-
Quebec
-
Montreal、Quebec、加拿大、H2X 3E4
- 招聘中
- Research Site
-
Montreal、Quebec、加拿大、H2W 1S6
- 招聘中
- Research Site
-
-
-
-
-
Kecskemét、匈牙利、6000
- 招聘中
- Research Site
-
Székesfehérvár、匈牙利、8000
- 招聘中
- Research Site
-
Tatabánya、匈牙利、2800
- 完全的
- Research Site
-
Törökbálint、匈牙利、2045
- 招聘中
- Research Site
-
-
-
-
-
Liuying、台湾、736
- 招聘中
- Research Site
-
New Taipei City、台湾、235
- 招聘中
- Research Site
-
Tainan、台湾、70403
- 招聘中
- Research Site
-
Taipei、台湾、10002
- 招聘中
- Research Site
-
Taipei、台湾、11217
- 招聘中
- Research Site
-
-
-
-
-
Ankara、土耳其(türkiye)、06800
- 招聘中
- Research Site
-
Ankara、土耳其(türkiye)、06010
- 招聘中
- Research Site
-
Ankara、土耳其(türkiye)、06500
- 招聘中
- Research Site
-
Istanbul、土耳其(türkiye)、34722
- 招聘中
- Research Site
-
Izmir、土耳其(türkiye)、35575
- 招聘中
- Research Site
-
-
-
-
-
Aviano、意大利、33081
- 招聘中
- Research Site
-
Brescia、意大利、25123
- 招聘中
- Research Site
-
Catanzaro、意大利、88100
- 撤销
- Research Site
-
Florence、意大利、50134
- 招聘中
- Research Site
-
Genova、意大利、16100
- 招聘中
- Research Site
-
Meldola、意大利、47014
- 招聘中
- Research Site
-
Milan、意大利、20162
- 招聘中
- Research Site
-
Monza、意大利、20900
- 招聘中
- Research Site
-
Padova、意大利、35128
- 招聘中
- Research Site
-
Perugia、意大利、06156
- 招聘中
- Research Site
-
Pisa、意大利、56124
- 招聘中
- Research Site
-
Roma、意大利、00144
- 招聘中
- Research Site
-
Rozzano、意大利、20089
- 招聘中
- Research Site
-
-
-
-
-
Ghent、比利时、9000
- 完全的
- Research Site
-
Ghent、比利时、9000
- 招聘中
- Research Site
-
Roeselare、比利时、8800
- 招聘中
- Research Site
-
-
-
-
-
Avignon、法国、84902
- 招聘中
- Research Site
-
Bobigny、法国、93009
- 撤销
- Research Site
-
Bordeaux、法国、33076
- 招聘中
- Research Site
-
Limoges、法国、83000
- 招聘中
- Research Site
-
Rennes、法国、35000
- 招聘中
- Research Site
-
Rouen、法国、76031
- 招聘中
- Research Site
-
Suresnes、法国、92150
- 招聘中
- Research Site
-
Toulon、法国、83000
- 主动,不招人
- Research Site
-
-
-
-
-
Dublin、爱尔兰、D08 NHY1
- 招聘中
- Research Site
-
Dublin、爱尔兰、D07 R2WY
- 招聘中
- Research Site
-
Dublin、爱尔兰、D09 V2N0
- 招聘中
- Research Site
-
Galway、爱尔兰、H91 YR71
- 招聘中
- Research Site
-
-
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- 招聘中
- Research Site
-
-
California
-
Los Angeles、California、美国、90095
- 招聘中
- Research Site
-
Oakland、California、美国、94611
- 撤销
- Research Site
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- 招聘中
- Research Site
-
-
Florida
-
Stuart、Florida、美国、34994
- 完全的
- Research Site
-
-
Georgia
-
Gainesville、Georgia、美国、30501
- 撤销
- Research Site
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- Research Site
-
-
Maryland
-
Baltimore、Maryland、美国、21231
- 招聘中
- Research Site
-
Baltimore、Maryland、美国、21201
- 撤销
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Research Site
-
-
Minnesota
-
Saint Louis Park、Minnesota、美国、55426
- 完全的
- Research Site
-
-
Nebraska
-
Omaha、Nebraska、美国、68124
- 招聘中
- Research Site
-
-
New York
-
Buffalo、New York、美国、14263
- 撤销
- Research Site
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- 招聘中
- Research Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15212
- 招聘中
- Research Site
-
-
Tennessee
-
Chattanooga、Tennessee、美国、37404
- 招聘中
- Research Site
-
Memphis、Tennessee、美国、38120
- 招聘中
- Research Site
-
Nashville、Tennessee、美国、37232
- 招聘中
- Research Site
-
Nashville、Tennessee、美国、37203
- 招聘中
- Research Site
-
Nashville、Tennessee、美国、37203
- 撤销
- Research Site
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- Research Site
-
Houston、Texas、美国、77090
- 终止
- Research Site
-
-
Virginia
-
Fairfax、Virginia、美国、22031
- 招聘中
- Research Site
-
-
Washington
-
Edmonds、Washington、美国、98026
- 招聘中
- Research Site
-
Seattle、Washington、美国、98104
- 招聘中
- Research Site
-
-
-
-
-
Lisbon、葡萄牙、1169-050
- 招聘中
- Research Site
-
Lisbon、葡萄牙、1099-023
- 招聘中
- Research Site
-
Lisbon、葡萄牙、1400-038
- 招聘中
- Research Site
-
Lisbon、葡萄牙、1500-650
- 招聘中
- Research Site
-
Porto、葡萄牙、4200-072
- 招聘中
- Research Site
-
Porto、葡萄牙、4099-001
- 撤销
- Research Site
-
Porto、葡萄牙、4100-180
- 完全的
- Research Site
-
-
-
-
-
A Coruña、西班牙、15006
- 招聘中
- Research Site
-
Alicante、西班牙、03010
- 招聘中
- Research Site
-
Barcelona、西班牙、08036
- 招聘中
- Research Site
-
Barcelona、西班牙、8035
- 终止
- Research Site
-
Córdoba、西班牙、14004
- 招聘中
- Research Site
-
Madrid、西班牙、28040
- 招聘中
- Research Site
-
Majadahonda、西班牙、28250
- 招聘中
- Research Site
-
Málaga、西班牙、29010
- 招聘中
- Research Site
-
Reus、西班牙、43204
- 招聘中
- Research Site
-
Seville、西班牙、41009
- 招聘中
- Research Site
-
Terrassa、西班牙、08221
- 招聘中
- Research Site
-
Valencia、西班牙、46010
- 招聘中
- Research Site
-
-
-
-
-
Busan、韩国、48108
- 完全的
- Research Site
-
Chungcheongbuk-do、韩国、28644
- 撤销
- Research Site
-
Seongnam-si、韩国、13496
- 招聘中
- Research Site
-
Seoul、韩国、03080
- 招聘中
- Research Site
-
Seoul、韩国、05505
- 招聘中
- Research Site
-
Suwon、韩国、16247
- 招聘中
- Research Site
-
Suwon、韩国、440-746
- 招聘中
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB).
- WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ and bone marrow function.
- Provision of tumour samples (newly acquired or archival tumour tissue [≤ 6 months old]) to confirm Programmed death-ligand 1 (PD-L1) status, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) status.
- Adequate pulmonary function.
Exclusion Criteria:
- Participants with sensitising EGFR mutations or ALK translocations.
- Participants with baseline PD-L1 expression status <1% (Arms 6 and 7 only).
- Active or prior documented autoimmune or inflammatory disorders.
- Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active bleeding diseases, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement.
- History of another primary malignancy.
- Participants with small-cell lung cancer or mixed small-cell lung cancer.
- History of active primary immunodeficiency.
- History of non-infectious interstitial lung disease (ILD) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Participants who have preoperative radiotherapy treatment as part of their care plan.
- Participants who require or may require pneumonectomy, segmentectomies, or wedge resections, as assessed by their surgeon at baseline, to obtain potentially curative resection of primary tumour.
- QTcF (QT interval corrected by Fridericia's formula) interval ≥ 470 ms.
- Any medical contraindication to treatment with chemotherapy as listed in the local labelling.
- Participants with moderate or severe cardiovascular disease.
- Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment.
- Receipt of live attenuated vaccine within 30 days prior to the first dose of study interventions.
- Prior exposure to approved or investigational immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains), anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies. Participants who received agents targeting the adenosine pathway, anti-NKG2A, anti-HLA-E agents, and anti-LIF agents are also excluded. Participants who have received previous treatment with a TROP2 targeting ADC or with another ADC containing a chemotherapy agent that inhibits TOP1 activity are also excluded.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of study interventions.
- Active or uncontrolled infections including HBA, HBV, HCV, and HIV.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm 1: Oleclumab + Durvalumab + Platinum doublet chemotherapy (CTX)
Participants will receive Durvalumab + Oleclumab + CTX as neoadjuvant treatment and Durvalumab + Oleclumab as adjuvant treatment. Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery: Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin |
Participants will receive Durvalumab via intravenous route.
其他名称:
Participants will receive Oleclumab via intravenous route.
其他名称:
Pemetrexed/Cisplatin as chemotherapy Pemetrexed/Carboplatin as chemotherapy Carboplatin/Paclitaxel, as chemotherapy |
|
实验性的:Arm 2: Monalizumab + Durvalumab + CTX
Participants will receive Durvalumab + Monalizumab + CTX as neoadjuvant treatment and Durvalumab + Monalizumab as adjuvant treatment. Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery: Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin |
Participants will receive Durvalumab via intravenous route.
其他名称:
Pemetrexed/Cisplatin as chemotherapy Pemetrexed/Carboplatin as chemotherapy Carboplatin/Paclitaxel, as chemotherapy Participants will receive Monalizumab via intravenous route.
其他名称:
|
|
实验性的:Arm 3: Volrustomig (Dose Exploration) + CTX
Participants will receive Volrustomig + CTX as neoadjuvant treatment and Volrustomig as adjuvant treatment. Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery: Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin |
Pemetrexed/Cisplatin as chemotherapy Pemetrexed/Carboplatin as chemotherapy Carboplatin/Paclitaxel, as chemotherapy Participants will receive Volrustomig via intravenous route.
其他名称:
|
|
实验性的:Arm 4: Dato-DXd + durvalumab + single agent platinum
Participants will receive Dato-DXd + durvalumab + single agent platinum as neoadjuvant treatment and durvalumab as adjuvant treatment. Participants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery: Carboplatin or Cisplatin |
Participants will receive Durvalumab via intravenous route.
其他名称:
Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route. Carboplatin as chemotherapy Cisplatin as chemotherapy |
|
实验性的:Arm 5: AZD0171 + durvalumab + CTX
Participants will receive AZD0171 + durvalumab + CTX as neoadjuvant treatment and AZD0171 + durvalumab as adjuvant treatment. Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery: Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin |
Participants will receive Durvalumab via intravenous route.
其他名称:
Pemetrexed/Cisplatin as chemotherapy Pemetrexed/Carboplatin as chemotherapy Carboplatin/Paclitaxel, as chemotherapy Participants will receive AZD0171 via intravenous route. |
|
实验性的:Arm 6: Rilvegostomig + CTX
Participants will receive Rilvegostomig + CTX as neoadjuvant treatment and Rilvegostomig as adjuvant treatment. Participants will receive one of the following chemotherapy regimens, based on the tumour histology and Investigator's discretion, as part of their treatment regimen prior to surgery: Carboplatin/Paclitaxel Pemetrexed/Cisplatin Pemetrexed/Carboplatin |
Pemetrexed/Cisplatin as chemotherapy Pemetrexed/Carboplatin as chemotherapy Carboplatin/Paclitaxel, as chemotherapy Participants will receive Rilvegostomig via intravenous route. |
|
实验性的:Arm 7: Dato-DXd + Rilvegostomig + single agent platinum
Participants will receive Dato-DXd + Rilvegostomig + single agent platinum as neoadjuvant treatment and Rilvegostomig as adjuvant treatment. Participants will receive one of the following chemotherapy regimens, based on physician choice of as part of their treatment regimen prior to surgery: Carboplatin or Cisplatin |
Participants will receive datopotamab deruxtecan (Dato-DXd) via intravenous route. Carboplatin as chemotherapy Cisplatin as chemotherapy Participants will receive Rilvegostomig via intravenous route. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
病理完全缓解 (pCR) 的参与者人数
大体时间:从随机分组到首次研究干预后约 15 周
|
从随机分组到首次研究干预后约 15 周
|
|
出现不良事件 (AE) 和严重不良事件 (SAE) 的参与者人数
大体时间:直到最后一剂研究干预后的第 90 天(最多大约 3 年)
|
直到最后一剂研究干预后的第 90 天(最多大约 3 年)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
经历无事件生存 (EFS) 事件的参与者人数
大体时间:最长约 3 年
|
最长约 3 年
|
|
经历无病生存 (DFS) 事件的参与者人数
大体时间:最长约 3 年
|
最长约 3 年
|
|
接受手术切除的参与者人数
大体时间:从随机分组到首次研究干预后约 15 周
|
从随机分组到首次研究干预后约 15 周
|
|
具有主要病理反应 (mPR) 的参与者人数
大体时间:从随机分组到首次研究干预后约 15 周
|
从随机分组到首次研究干预后约 15 周
|
|
达到客观缓解率 (ORR) 的参与者人数
大体时间:从随机分组到首次研究干预后约 15 周
|
从随机分组到首次研究干预后约 15 周
|
|
总生存期(OS)
大体时间:最长约 3 年
|
最长约 3 年
|
|
具有抗研究药物抗体(ADA)的参与者人数
大体时间:从随机化到最后一剂研究干预后 3 个月(最长约 3 年)
|
从随机化到最后一剂研究干预后 3 个月(最长约 3 年)
|
|
基线 PD-L1 表达
大体时间:在筛选/基线
|
在筛选/基线
|
|
循环肿瘤 DNA (ctDNA) 的变化
大体时间:从随机化到最后一次研究干预后最多 24 个月(最多约 3 年)
|
从随机化到最后一次研究干预后最多 24 个月(最多约 3 年)
|
|
研究干预措施的血清浓度(Durvalumab/Oleclumab/Monalizumab/Volrustomig/Rivegostomig)
大体时间:从随机化到最后一剂研究干预措施(最长约 3 年)
|
从随机化到最后一剂研究干预措施(最长约 3 年)
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- D9077C00001
- 2021-003369-37 (EudraCT编号)
- 2023-508852-21-00 (注册表标识符:CTIS)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 共享时间框架
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 共享访问标准
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.